Trial reportThe Journal of clinical investigation2011
Activation of K(ATP) channels suppresses glucose production in humans.
Trial report in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01028846 (Central Mechanisms That Regulate Glucose Metabolism in Humans), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Central Mechanisms That Regulate Glucose Metabolism in Humans
Who cites it
55 citing papers in PubMed, 106 citations in OpenAlex.
- Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.The Journal of clinical endocrinology and metabolism · 2026Trial
- Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.The Journal of clinical endocrinology and metabolism · 2023Trial
- Exercise restores brain insulin sensitivity in sedentary adults who are overweight and obese.JCI insight · 2022Trial
- A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.PloS one · 2019Trial
- Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.Journal of clinical psychopharmacology · 2018Trial
- Trial
- Trial
- Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans.Diabetes · 2013Trial
- Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women.Diabetes · 2012Trial
- Diazoxide choline extended-release (DCCR) use in Prader-Willi syndrome: patient selection, dosing, and management.Journal of the Endocrine Society · 2026Review
- The autonomic nervous system in the regulation of glucose and lipid metabolism.Nature reviews. Endocrinology · 2026Review
- The Role of the Arcuate Nucleus in Regulating Hunger and Satiety in Prader-Willi Syndrome.Current issues in molecular biology · 2025Review
- Brain Defense of Glycemia in Health and Diabetes.Diabetes · 2024Review
- Exercise as a Therapeutic Strategy for Obesity: Central and Peripheral Mechanisms.Metabolites · 2024Review
- The insulin resistant brain: impact on whole-body metabolism and body fat distribution.Diabetologia · 2024Review
- Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.Journal of neurodevelopmental disorders · 2024Article
- Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.Obesity (Silver Spring, Md.) · 2024Article
- Review
- Liver insulinization as a driver of triglyceride dysmetabolism.Nature metabolism · 2023Review
- Clinical Trials in Prader-Willi Syndrome: A Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Increased endogenous glucose production (EGP) is a hallmark of type 2 diabetes mellitus. While there is evidence for central regulation of EGP by activation of hypothalamic ATP-sensitive potassium (K(ATP)) channels in rodents, whether these central pathways contribute to regulation of EGP in humans remains to be determined. Here we present evidence for central nervous system regulation of EGP in humans that is consistent with complementary rodent studies. Oral administration of the K(ATP) channel activator diazoxide under fixed hormonal conditions substantially decreased EGP in nondiabetic humans and Sprague Dawley rats. In rats, comparable doses of oral diazoxide attained appreciable concentrations in the cerebrospinal fluid, and the effects of oral diazoxide were abolished by i.c.v. administration of the K(ATP) channel blocker glibenclamide. These results suggest that activation of hypothalamic K(ATP) channels may be an important regulator of EGP in humans and that this pathway could be a target for treatment of hyperglycemia in type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.